Micelle BioPharma

Riviera Beach, United States Founded: 2018 • Age: 8 yrs Acquired By Strides Pharma Science
Developer of orphan drugs for treating sickle cell based diseases
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Micelle BioPharma

Micelle BioPharma is a company based in Riviera Beach (United States) founded in 2018 was acquired by Strides Pharma Science in August 2019. Micelle BioPharma operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Alcresta, among others.

  • Headquarter Riviera Beach, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Micelle BioPharma

Premium access

Detailed funding history for Micelle BioPharma

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Micelle BioPharma

Micelle BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Strides Pharma Science.

All
Institutional
Investor Description Founded Year Domain Location
Generic, semi-solid, and liquid dosage forms are manufactured.
Locked Locked Locked
Premium access

Investor details for Micelle BioPharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Micelle BioPharma

Investments
Premium access

Investment portfolio details for Micelle BioPharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Micelle BioPharma

Premium access

Detailed financials for Micelle BioPharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Micelle Biopharma Comparisons

Micelle BioPharma Primary company
Description
Developer of orphan drugs for treating sickle cell based dis...
Location
Riviera Beach, United States
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Micelle BioPharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Micelle BioPharma

Micelle BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Alcresta, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
Locked Locked Locked
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
Locked Locked Locked
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
Locked Locked Locked
Therapeutics for gastrointestinal diseases are developed and provided.
Locked Locked Locked
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
Locked Locked Locked
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
Premium access

Detailed competitors of Micelle BioPharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Micelle Biopharma

Premium access

Complete news archive for Micelle BioPharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Micelle BioPharma

Micelle BioPharma was founded in 2018.

Micelle BioPharma is headquartered in Riviera Beach, United States. It is registered at Riviera Beach, Florida, United States.

Founded in 2018, Micelle BioPharma is based in Riviera Beach, United States, and operates in the biopharmaceutical sector. Drugs for sickle cell disease in children are developed via the Advanced Lipid Technologies platform. The pipeline includes SC411 in phase II trials for SCD treatment, SC401 for managing high triglycerides linked to cardiovascular and liver issues, SC403 for addressing fatty acid malabsorption, and SC410 for non-alcoholic fatty liver disease and steatohepatitis.

Micelle BioPharma's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.

Micelle BioPharma has 1 investor. Key investors include Strides Pharma Science.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available